Perilymphatic application of α-melanocyte stimulating hormone ameliorates hearing loss caused by systemic administration of cisplatin

Wolters, Francisca L.C.; Klis, Sjaak F.L.; Hamers, Frank P.T.; Groot, John C.M.J. de; Smoorenburg, Guido F.

doi:10.1016/s0378-5955(03)00396-4

Cited by 10 publications

(5 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This finding may open the door to pharmacologically targeting cochlear melanocytes (intermediate cells) to possibly prevent or delay age-related hearing loss. Synthetic analogs of melanocyte stimulating hormone (MSH) have already been developed for human use (Abdel-Malek 2010), and animal studies have demonstrated a protective role of MSH against ototoxicity from cisplatin in which the mechanism remains unclear (Wolters et al 2003(Wolters et al , 2004. Current advances in administering drugs directly to the middle and inner ear via transtympanic injections (Bowe and Jacob 2010) also raise the possibility of precisely targeting pharmacological agents to the inner ear without systemic effects.…”

Section: Resultsmentioning

confidence: 99%

Association of Skin Color, Race/Ethnicity, and Hearing Loss Among Adults in the USA

Lin

Maas

Chien

et al. 2011

JARO

112

View full text Add to dashboard Cite

Epidemiologic studies of hearing loss in adults have demonstrated that the odds of hearing loss are substantially lower in black than in white individuals. The basis of this association is unknown. We hypothesized that skin pigmentation as a marker of melanocytic functioning mediates this observed association and that skin pigmentation is associated with hearing loss independent of race/ethnicity. We analyzed cross-sectional data from 1,258 adults (20-59 years) in the 2003-2004 cycle of the National Health and Nutritional Examination Survey who had assessment of Fitzpatrick skin type and pure-tone audiometric testing. Audiometric thresholds in the worse hearing ear were used to calculate speech-(0.5-4 kHz) and high-frequency (3-8 kHz) pure-tone averages (PTA). Regression models were stratified by Fitzpatrick skin type or race/ethnicity to examine the association of each factor with hearing loss independent of the other. Models were adjusted for potential confounders (demographic, medical, and noise exposure covariates). Among all participants, race/ethnicity was associated with hearing thresholds (black participants with the best hearing followed by Hispanics and then white individuals), but these associations were not significant in analyses stratified by skin color. In contrast, in race-stratified analyses, darker-skinned Hispanics had better hearing than lighterskinned Hispanics by an average of −2.5 dB hearing level (HL; 95% CI, −4.8 to −0.2) and −3.1 dB HL (95% CI, −5.3 to −0.8) for speech and high-frequency PTA, respectively. Associations between skin color and hearing loss were not significant in white and black participants. Our results demonstrate that skin pigmentation is independently associated with hearing loss in Hispanics and suggest that skin pigmentation as a marker of melanocytic functioning may mediate the strong association observed between race/ethnicity and hearing loss.

show abstract

Section: Resultsmentioning

confidence: 99%

Association of Skin Color, Race/Ethnicity, and Hearing Loss Among Adults in the USA

Lin

Maas

Chien

et al. 2011

JARO

112

View full text Add to dashboard Cite

show abstract

“…The authors proposed that this effect may be induced by the antagonistic action of α-MSH on cytokineinduced ischemic brain damage caused by free radical injury. Furthermore, daily administration of α-MSH has been shown to protect the inner ear from cis-platinum ototoxicity (Wolters et al 2004).…”

Section: Discussionmentioning

confidence: 99%

Zucker diabetic fatty rats, a model for type 2 diabetes, develop an inner ear dysfunction that can be attenuated by losartan treatment

et al. 2015

View full text Add to dashboard Cite

Hearing loss secondary to diabetes remains under debate. In our study, we used Zucker Diabetic Fatty (ZDF) rats as an animal model of type 2 diabetes to investigate whether (1) hearing ability impairment and structural alterations of the inner ear occur in diabetes and (2) an angiotensin II receptor blocker (losartan) can protect rats from diabetic damage. Homozygous mutants were treated with a placebo or losartan and heterozygous animals served as non-diabetic controls. All animals underwent immunohistochemical and electronmicroscopical analysis. Functional testing of hearing ability was performed by click-evoked auditory brainstem responses. The present study showed significant sensorineural hearing impairment in placebo-treated diabetic rats (hearing threshold, 45.0 ± 2.1 dB SPL) compared to both non-diabetic controls (34.7 ± 4 dB SPL) and losartan-treated diabetic rats (36.1 ± 7.4 dB SPL). Concurrently, the functional decline in the placebo-treated rats was associated with significant morphological abnormalities, particularly in the intermediate cells of the stria vascularis and with strial dysfunction. These degenerative changes were indicated by the down-regulation of several pumps, ionic and cellular channels, which are involved in the cycling of K(+) and the maintenance of the endocochlear potential essential for the hearing process. Thus, the inner ear can be regarded as a target organ during hyperglycemic disorders and a metabolically induced "diabetic otopathy" may be added to angiopathy, nephropathy and neuropathy as a specific complication of diabetes mellitus. Blockade of the angiotensin II receptor can prevent this "diabetic otopathy" despite hyperglycemic serum levels.

show abstract

“…Antioxidant erdosteine [ N -(carboxymethythioacetyl)homocysteine thiolactone] was also reported to partially protect the cochlea against cisplatin toxicity in vivo . Melanocortins, like the adrenocorticotropic hormone (ACTH)-analogue ORG 2766 and α-melanocyte stimulating hormone (α-MSH), can delay cisplatin-induced ototoxicity. − The hearing loss caused by local cisplatin administration in guinea pigs was delayed by co-treatment with α-MSH . Peroxynitrite decomposition catalysts (PNDCs) can potentially mitigate nitrative stress-induced otopathology .…”

Section: Platinum-based Combinations Based On the Underlying Molecula...mentioning

confidence: 99%

Platinum-Based Combination Therapy: Molecular Rationale, Current Clinical Uses, and Future Perspectives

Wang

Sun

et al. 2020

J. Med. Chem.

View full text Add to dashboard Cite

Platinum drugs are common in chemotherapy, but their clinical applications have been limited due to drug resistance and severe toxic effects. The combination of platinum drugs with other drugs with different mechanisms of anticancer action, especially checkpoint inhibitors, is increasingly popular. This combination is the leading strategy to improve the therapeutic efficiency and minimize the side effects of platinum drugs. In this review, we focus on the mechanistic basis of the combinations of platinum-based drugs with other drugs to inspire the development of more promising platinum-based combination regimens in clinical trials as well as novel multitargeting platinum drugs overcoming drug resistance and toxicities resulting from current platinum drugs.

show abstract

Perilymphatic application of α-melanocyte stimulating hormone ameliorates hearing loss caused by systemic administration of cisplatin

Cited by 10 publications

References 38 publications

Association of Skin Color, Race/Ethnicity, and Hearing Loss Among Adults in the USA

Association of Skin Color, Race/Ethnicity, and Hearing Loss Among Adults in the USA

Zucker diabetic fatty rats, a model for type 2 diabetes, develop an inner ear dysfunction that can be attenuated by losartan treatment

Platinum-Based Combination Therapy: Molecular Rationale, Current Clinical Uses, and Future Perspectives

Contact Info

Product

Resources

About